Innate Pharma (IPHA) Return on Equity (2023 - 2024)
Historic Return on Equity for Innate Pharma (IPHA) over the last 6 years, with Q2 2025 value amounting to 7.99%.
- Innate Pharma's Return on Equity fell 78100.0% to 7.99% in Q2 2025 from the same period last year, while for Jun 2025 it was 7.99%, marking a year-over-year decrease of 78100.0%. This contributed to the annual value of 0.0% for FY2022, which is 600.0% up from last year.
- Per Innate Pharma's latest filing, its Return on Equity stood at 7.99% for Q2 2025, which was down 78100.0% from 3.02% recorded in Q4 2024.
- Innate Pharma's 5-year Return on Equity high stood at 0.14% for Q4 2023, and its period low was 7.99% during Q2 2025.
- Moreover, its 5-year median value for Return on Equity was 0.88% (2023), whereas its average is 1.68%.
- As far as peak fluctuations go, Innate Pharma's Return on Equity skyrocketed by 6900bps in 2024, and later tumbled by -78100bps in 2025.
- Innate Pharma's Return on Equity (Quarter) stood at 0.9% in 2021, then surged by 35bps to 0.58% in 2022, then surged by 76bps to 0.14% in 2023, then tumbled by -2085bps to 3.02% in 2024, then crashed by -165bps to 7.99% in 2025.
- Its Return on Equity stands at 7.99% for Q2 2025, versus 3.02% for Q4 2024 and 0.19% for Q2 2024.